Guess which high-flying ASX All Ords stock was just halted ahead of a key FDA decision

The ASX All Ords stock is awaiting an important announcement from the US FDA.

| More on:
woman sitting at desk holding hand up in stop motion

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The All Ordinaries Index (ASX: XAO) is up 0.1% in morning trade today, but this ASX All Ords stock isn't going anywhere just yet.

Shares in the clinical dermatology company closed at 34 cents apiece yesterday, which sees the stock up almost 18% in five days.

Today shares in the ASX All Ords stock entered a trading halt pending a key approval announcement from the United States Food & Drug Administration (FDA). Shares are expected to resume trading this Friday.

Any guesses?

If you said Botanix Pharmaceuticals Ltd (ASX: BOT), go to the head of the virtual class.

Here's what's happening.

What's happening with the ASX All Ords stock?

Last Wednesday, 12 June, Botanix announced that it had submitted the last label materials to the FDA for its prescription product Sofdra. Sofdra is developed to treat excessive underarm sweating. Also known as primary axillary hyperhidrosis, for our medically inclined readers.

That announcement saw the ASX All Ords stock charge higher over the next three trading days.

Investor enthusiasm looks to have been piqued by the company noting that its labelling discussions present the final step before the "anticipated FDA approval of Sofdra". Botanix said its been in discussions with the FDA on product carton design and the wording of information to be provided to patients and physicians about Sofdra.

Commenting on the anticipated approval that sees the ASX All Ords stock in a trading halt today, Botanix CEO Howie McKibbon said:

Our team has been highly focused on completing these last label components, well in advance of approval.

Our label and packaging materials are an important part of the materials that we will use to communicate important safety and efficacy information upon approval of Sofdra.

The company said that FDA approval for Sofdra remains on target for this Friday, 21 June. Upon approval, it said that Sofdra will be the first new chemical entity approved for excessive underarm sweating.

Atop of Sofdra, the ASX All Ords stock has a range of other products in late-stage clinical development to potentially treat a variety of dermatology conditions.

Botanix share price snapshot

If you look back to the chart up top, you'll see just how strong the Botanix share price has performed over the past months.

In 2024 alone, the ASX All Ords share has gained 76%.

Investors who bought shares 12 months ago will be sitting on gains of 205%.

And savvy investors who bought shares at the very end of 2022 (30 December) will have seen those shares rocket by 570%.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A businesswoman exhales a deep sigh after receiving bad news, and gets on with it.
Earnings Results

Cochlear share price sinks 10% on half-year result disappointment

Let's see why investors are hitting the sell button this morning.

Read more »

Woman flexes muscles after donating blood.
Healthcare Shares

The CSL share price hit a 52-week low this week. Is it time to buy?

Is this beaten-up biotech a healthy opportunity?

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Sigma share price up 9% on first day of trading post-merger with Chemist Warehouse

It's a post-merger party for Sigma Healthcare shareholders today.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 135% in a year, why this ASX 200 healthcare stock is 'on track to become a truly great Australian success'

A leading fund manager expects more strong performance from this surging ASX 200 healthcare stock.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

With revenue up 9%, why does the NIB share price keep falling?

Will the ailing share price make a full recovery?

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Guess how much $5,000 invested in Sigma shares in December 2023 is worth now!

Sigma shares have soared over the past year alongside the merger with Chemist Warehouse.

Read more »

Woman with headphones on relaxing and looking at her phone happily.
Healthcare Shares

Everything you need to know about the latest CSL dividend

CSL's latest dividend should be turning investors' heads...

Read more »

thoughtful investor sitting at computer
Healthcare Shares

What are brokers saying about CSL shares after the selloff?

The biotech giant's shares hit a 52-week low yesterday. Is this a buying opportunity?

Read more »